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Abstract: Given the emergence of breakthrough infections, new variants, and concerns of waning
immunity from the primary COVID-19 vaccines, booster shots emerged as a viable option to shoreup protection against COVID-19. Following the recent authorization of vaccine boosters among
vulnerable Americans, this study aims to assess COVID-19 vaccine booster hesitancy and its associated factors in a nationally representative sample. A web-based 48-item psychometric valid
survey was used to measure vaccine literacy, vaccine confidence, trust, and general attitudes towards
vaccines. Data were analyzed through Chi-square (with a post hoc contingency table analysis) and
independent-sample t-/Welch tests. Among 2138 participants, nearly 62% intended to take booster
doses and the remaining were COVID-19 vaccine booster hesitant. The vaccine-booster-hesitant
group was more likely to be unvaccinated (62.6% vs. 12.9%) and did not intend to have their children
vaccinated (86.1% vs. 27.5%) compared to their non-hesitant counterparts. A significantly higher
proportion of booster dose hesitant individuals had very little to no trust in the COVID-19 vaccine information given by public health/government agencies (55% vs. 12%) compared to non-hesitant ones.
The mean scores of vaccine confidence index and vaccine literacy were lower among the hesitant
group compared to the non-hesitant group. Compared to the non-hesitant group, vaccine hesitant
participants were single or never married (41.8% vs. 28.7%), less educated, and living in a southern
region of the nation (40.9% vs. 33.3%). These findings underscore the need of developing effective
communication strategies emphasizing vaccine science in ways that are accessible to individuals
with lower levels of education and vaccine literacy to increase vaccination uptake.
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1. Introduction
The coronavirus-19 disease (COVID-19) has caused significant mortality and morbidity worldwide [1–3]. Vaccines against COVID-19 were developed by early 2021 and
demonstrated outstanding protection against COVID-19 infections, hospitalizations, and
deaths [4–6]. There has been a considerable discussion about the eventual need for a
booster dose of COVID-19 vaccines, primarily in response to concerns about possible
waning immunity, the transmission of breakthrough infections, and the emergence of new
viral variants with increased transmissibility [7–10].
While protection against hospitalizations and deaths remained robust, several studies
appeared to show a decline in protection against COVID-19 infections a few months after
the initial vaccination. In a retrospective study in Israel, rates of breakthrough infections
amongst fully vaccinated patients with the Pfizer-BioNTech vaccine were considerably
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higher among those vaccinated earlier than those who were immunized later [11]. Analysis
of an observational study among fully vaccinated nursing home residents revealed that
the vaccine efficacy dropped from 74.7% to only 53.1% in a few months [12]. Another
study found that vaccines’ effectiveness against infections amongst New Yorkers waned
from 91.7% to 79.8% [13]. However, this study also found that the vaccine remains highly
effective against hospitalizations. Other studies reported a decline in vaccine effectiveness
over time and increased potential for hospitalizations following breakthrough infections
among immunocompromised patients [12,14–17]. In addition, a study performed in Israel
demonstrated that administering a booster dose five months after completing the initial
two-dose regimen increased protection against infection by 11.3-fold and severe illness
by 19.5-fold [18]. Due to the potential for waning immunity and the emergence of new
virus variants, there have been calls for the introduction of booster shots. Some argue that
booster shots are not presently needed in the general population but concede that they may
ultimately be needed because of these considerations [19].
Many countries have already started administering booster doses in the wake of
breakthrough infections, arrivals of new variants, and a decline in long-term protection.
As of 20 September 2021 (at the time of writing this manuscript), over twenty-one million
booster doses have been given across the world [20]. Israel has been administering booster
shots since 30 July 2021 [18,21]. In the United States of America (U.S.A.), the Center for
Disease Control and Prevention (CDC) recommends that immunocompromised patients
receive a booster shot [15]. Furthermore, the U.S. Food and Drug Administration (FDA)
Vaccines and Related Biological Advisory Committee voted unanimously on 17 September
2021 to recommend a booster dose for individuals 65 years of age and older and individuals
at high risk of severe COVID-19 [22]. Similarly, the United Kingdom (UK) is also planning
to administer boosters in the autumn of 2021 [23,24].
The use of booster doses will at some point play an essential role in the public health
response to the pandemic. However, the public’s acceptance of a booster dose emerges as a
potential concern. As COVID-19 vaccination efforts have been hampered by hesitancy and
mistrust [25–27], COVID-19 booster shot initiatives will likely face similar challenges. In
order to design interventions and increase the uptake of the booster dose, it is imperative
to quantify the baseline acceptance levels towards the booster dose. Therefore, this study
aims to investigate acceptance for future booster doses and its associated factors among
vaccine-eligible Americans.
2. Methods
2.1. Study Design, Setting, and Sampling
Data for this cross-sectional, descriptive, and exploratory study were collected from
14 July to 19 July 2021, using a commercial data collection and administration agency,
Qualtrics, to recruit a nationally representative sample by gender, race, ethnicity, and
regional distribution. Qualtrics is a marketing research company which utilizes its highquality research panels and quota sampling to recruit specific target population groups.
Additional details about the sampling strategy can be accessed at https://www.qualtrics.
com/research-services/online-sample/ (accessed on 22 September 2021). Miller and
colleagues have also described Qualtrics’ recruitment process for their commercial research
panels and the advantages of online research panels and quota sampling techniques over
traditional sampling methods [28]. Qualtrics recruits a panel of participants through a
convenience sampling of sources acquired from partnerships with over 20 online sample
providers. This recruitment method enables Qualtrics to provide researchers with diverse
datasets that represent the population under study. The respondents are first randomly
selected by the sample partners through traditional, actively managed, double-opt-in
market panels that allow selecting participants that are likely to qualify. Social media can
also be used to amass respondents when necessary.
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2.2. Study Population and Selection Criteria
The study samples were obtained from currently available pools of research participants, who have consented to be communicated for future studies. To avoid heavy
dependence on a single segment of the population, Qualtrics pooled samples from different
sources across the nation. The recruitment of respondents was performed in an enforced
quota sampling fashion to create a pool of participants representing the current U.S. demography. The enforced quota constraints closely matched the U.S. Census, as shown
below in the Table 1.
Table 1. Quota constraints to recruit nationally representative sample.

Demography

Characteristics

Study Sample (%)

Census
Distribution *,
Population
Parameters (%)

Gender

Female
Male

49.7
47.6

50.8
49.2

Ethnicity

Non-Hispanic White
Non-Hispanic Black
Hispanic
Asian
Others

61.9
12.3
17.4
5.3
3.1

60.1
13.4
18.5
5.9
2.1

Region

Midwest
Northeast
South
West

21.33
18.02
37.27
23.38

20.8
17.1
38.3
23.9

* https://www.census.gov/quickfacts/fact/table/US/PST045219 (accessed on 13 November 2021).

Current U.S. residents aged at least 18 years with the ability to provide voluntary
informed consent and understand English were eligible to participate in this study. Participants who did not meet these criteria were excluded from the study. Screening questions
were added at the start of the survey to ensure adherence to the study’s eligibility criteria.
In order to minimize self-selection and response bias, details of the actual survey were
not shown until the participants passed the screening criteria. Survey respondents were
compensated for their time through incentives, which may include cash, airline miles,
charitable donations, sweepstakes entrance, vouchers, or gift certificates.
2.3. Ethical Considerations
The Institutional Review Board (IRB) granted this study a category two exemption
(protocol # 1762717-2). Participants were informed of the significance and the objectives of
the study. Participation in the survey was voluntary. No personal identifiers were acquired.
2.4. Quality Control and Data Privacy
Multiple data quality features were used in the survey to ensure data integrity and
unique responses from each study participant. Digital fingerprinting and preventing
ballot box stuffing restricted participants from answering the survey more than once.
Participants were excluded if they completed the survey significantly quicker than other
survey respondents due to the high possibility of a lack of thoughtfulness in their responses.
Qualtrics and the research team members abided by all data privacy laws and regulations.
The Qualtrics database does not store any confidential information of the respondents or
panelists. Deidentified data were provided to the researchers in an excel sheet safeguarded
on a password-protected device in a locked office. Access to these files was restricted to
research team members.
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2.5. Survey Instrument
This study utilized a 48-item web-based survey consisting of several psychometrically
valid and reliable tools to measure the following constructs: attitudes towards other
vaccines in general (9 items), confidence towards COVID-19 booster dose (8 items), vaccine
literacy (14 items), and demographic questions (17 items). Questions related to general
attitudes towards vaccines were adapted from prior studies that assessed vaccine hesitancy
using a standardized tool to measure vaccine attitude [29,30]. To measure vaccine literacy,
a self-reported questionnaire was used, originally based on the Ishikawa test for chronic
non-communicable diseases [31]. The vaccine confidence index (VCI) was modified to
apply to the COVID-19 vaccine specifically. This VCI was previously used in studies
analyzing choice architecture for the influenza vaccine and in vaccine confidence projects
in many countries [30,32,33].
2.6. Sampling and Sample Size
Participation and completion rates are difficult to calculate because respondents were
sourced via various methods (e.g., email, online/mobile games, dashboard where they
self-select into the survey, apps, etc.), making these values difficult to pinpoint. Qualtrics
aggregates many online panel resources, and most use what are called “dynamic surveys”
that are distributed in a dashboard style, where respondents see a dashboard of surveys
that they likely qualify for. This can also include app-based recruitment, and a multitude of
other methods. Some people may receive email notifications, but this is an older system of
distributing surveys that is not widely used. The tracking of the respondents starts as soon
as they choose to engage with the survey specifically; however, there is no specific survey
invite that everyone sees across the project and, therefore, exactly how many invites are
sent out cannot be reported. Out of the total survey entrants, screening criteria, speeding
checks, quality control, and quota constraints are applied by Qualtrics to ensure delivery
of high-quality and complete data to abide by the contractual agreement made between
researchers and Qualtrics. Out of the total survey entrants, screening criteria, speeding
checks, quality control, quota constraints are applied by Qualtrics to ensure the delivery
of high-quality and complete data to abide by the contractual agreement made between
researchers and Qualtrics. There was a total of 2138 complete entries in the dataset provided
by Qualtrics and missing data analysis was not warranted. The Checklist for Reporting
Results of Internet E-Surveys (CHERRIES) guidelines was followed to provide a thorough
description of this web-based survey’s validity [34].
2.7. Sample Size Justification
G*Power software was used to conduct power analyses [34,35] to determine whether
the sample was sufficient to detect the hypothesized effects. Using Cohen’s benchmarks of
small effect sizes related to each statistical test (0.1 for Chi-square and 0.2 for t-test), alpha
level 5%, and 95% power, the maximum sample size required was 1979. After factoring in
10% missing data, the estimated sample size was 2177, comparable to the current sample
size utilized in this study.
2.8. Data Analyses
All analyses were conducted using IBM SPSS v.26 (IBM Corp, Armonk, NY, USA) and
SAS 9.4. statistical software. Descriptive statistics were performed to compute the mean,
standard deviations, counts, and proportions. Exploratory analyses were utilized to investigate the data distribution and assumptions. A Chi-square test with a post hoc contingency
analysis was conducted to compare categorical variables among booster hesitant and nonhesitant groups by Chi-square test. The observed p-values were Bonferroni-corrected in
multiple comparisons [36]. Continuous variables, such as the vaccine confidence, attitudes,
and vaccine literacy, were compared using independent-sample t-tests or Welch’s t-test
(wherever appropriate). Levene’s test for equality of variances was utilized to check the
assumption of homogeneity of variances. A bootstrapping technique was also used to
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validate the statistical significance among groups. Effect sizes were computed to measure
the strength of the effect that emerged from the sampled data. A subgroup analysis to
compare vaccine literacy scores among hesitant and non-hesitant participants who have
had “a lot” of trust in COVID-19 vaccine information was also conducted. A Checklist for
statistical Assessment of Medical Papers (the CHAMP statement) was used for statistical
reporting [37]. A multivariate logistic regression model was fit to generate an adjusted
odds ratio. Estimates for the parameters were obtained through the maximum likelihood
estimation method with 95% Wald’s confidence limits for the logistic model. The final
model was selected based upon the Akaike information criterion (AIC) and the Schwarz
criterion (SC) [38]. The significance level was set at 5%.
3. Results
Out of 2138 total respondents, 1322 (61.8%, 95% CI: 59.7–63.9%) were willing to take
the booster dose, and the remaining 38.2% (95% CI: 36.1–40.3%) were booster dose hesitant
(Table 2). In comparison to those willing to take a booster dose, members of the booster dose
hesitant group were relatively younger (42.5 years vs. 47.6 years), unvaccinated (62.6%, 95%
CI: 59.2–65.9% vs. 12.9%, 95% CI: 11.1–14.8%; p < 0.001), and did not intend to have their
children vaccinated (86.1%, 95% CI: 82.4–89.2% vs. 27.5%, 95% CI: 23.8–31.4%; p < 0.001).
As shown in Table 2, 55.4% (95% CI: 51.9–58.8%) of females were in the hesitant group,
compared to 46.2% (95% CI: 43.5–48.9%) in the non-hesitant group (p < 0.001), and the effect
size, Cramer’s V, was small. Political affiliation also plays a significant role in determining
whether one will get a booster dose as nearly 33% (95% CI: 29.5–36.0%) of Republicans were
in the hesitant group, compared to 23% (95% CI: 20.9–25.5%) in the non-hesitant group
(p < 0.001). Religiously unaffiliated participants were significantly more vaccine-hesitant
than non-hesitant (35.5%, 95% CI: 32.3–38.9% vs. 27.4%, 95% CI: 24.9–29.8%; p < 0.001). As
compared to the vaccine non-hesitant group, vaccine hesitant participants were single or
never married (41.8%, 95% CI: 38.4–45.3% vs. 28.7%, 95% CI: 26.3–31.3%), uninsured (16.4%,
95% CI: 13.5–18.6% vs. 7.0%, 95% CI: 5.6–8.5%), less educated, and living in a southern
region of the nation (40.9%, 95% CI: 37.5–44.4% vs. 33.3%, 95% CI: 30.7–35.9%; p < 0.001,
Table 2). Living with a vulnerable family member, having COVID-19 positive friends or
family members, and having pre-existing conditions were also significantly associated
with booster dose acceptability. However, the effect size was small, ranging from 0.10
to 0.15 (Table 2). The results of multivariate logistic regression analysis indicated that
acceptability towards primary series of COVID-19 vaccination, parents’ willingness to have
their children vaccinated, and political affiliation were significant predictors of booster dose
acceptability (Appendix A Figure A1). After controlling for all confounders, participants
who had already received a primary dose of COVID-19 vaccine were more than thrice likely
to accept booster doses (OR 3.32, 95% CI: 2.20–5.01; Appendix A Figure A1). Parents who
were willing to have their children vaccinated had significantly higher odds of booster dose
acceptability (OR 10.3; 95% CI: 6.78–15.77). Among all demographic variables, political
affiliation was a significant predictor of booster dose acceptability. Being a democrat
increased the likelihood of booster dose acceptability by nearly twice (OR 1.90, 95% CI:
1.17–3.10).
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Table 2. Intention of taking booster dose by sample characteristics (n = 2138).
Intention to Take Booster Dose
Variable Name

Categories

Yes
(n = 1322)

No
(n = 816)

p Value

Statistics

ES

Vaccinated status

Yes
No

1151 (87.1)
171 (12.9)

305 (37.4)
511 (62.6)

<0.001

573.43

0.518

Intention to have children
vaccinated *

Yes
No

406(72.5)
154 (27.5)

59 (13.9)
365 (86.1)

<0.001

332.277

0.581

Age (Mean ± SD)

-

47.62 ± 19.3

42.47 ± 17.7

Male
Female
Other

680 (51.4)
611 (46.2)
31 (2.3)

338 (41.4)
452 (55.4)
21 (2.6)

<0.001
<0.001
0.2

29.391

0.117

Gender

842 (63.7)
156 (11.8)
208 (15.7)

513 (62.9)
121 (14.8)
125 (15.3)

0.7
0.05
0.8

5.677

0.052

Race/ethnicity

White
African American
Hispanic
Other (including multiracial
groups)

116 (8.8)

57 (7.0)

0.1

Divorced/Separated/Widowed
Married
Single, never married

283(21.4)
659 (49.8)
380 (28.7)

189(23.2)
286 (35.0)
341(41.8)

0.3
<0.001
<0.001

51.167

0.155

Marital status

266 (20.1)
345 (26.1)
279 (21.1)
382 (28.9)
38 (2.9)
12 (0.9)

249 (30.5)
137 (16.8)
77 (9.4)
284 (34.8)
55 (6.7)
14 (1.7)

<0.001
<0.001
<0.001
<0.001
<0.001
0.09

108.969

0.226

Education

High school diploma or GED
4-year college degree
Graduate level degree
Some college
Some high school
Other

Health insurance

Yes
No

1214 (93.0)
92 (7.0)

665 (83.6)
130 (16.4)

<0.001

50. 668

0.154

Friends/Family tested
positive for COVID-19

Yes
No

674 (51.5)
635 (48.5)

350 (43.9)
448 (56.1)

0.001

16.797

0.089

Living with vulnerable/
immunocompromised person

Yes

496 (38.2)

196 (24.9)

<0.001

45.802

0.146

No

803 (61.8)

591(75.1)

Yes

647 (50.0)

298 (38.0)

<0.001

34.162

0.126

No

648 (50.0)

487 (62.0)
21.304

0.100

110.494

0.227

28.179

0.115

Pre-existing conditions

Region

Political affiliation

Religion

Midwest

288 (21.8)

193 (23.7)

0.3

Northeast

280 (21.2)

124 (15.2)

<0.001

South

440 (33.3)

334 (40.9)

<0.001

West

314 (23.8)

165 (20.2)

0.06

Democrat

627 (47.4)

203 (24.9)

<0.001

Republican

306 (23.1)

267 (32.7)

<0.001

Independent

317 (24.0)

269 (33.0)

<0.001

Others

14 (1.1)

11(1.3)

0.5

Roman Catholic

344 (26.0)

141 (17.3)

<0.001

Protestant

297 (22.5)

181 (22.2)

0.8

Religiously unaffiliated

362 (27.4)

290 (35.5)

<0.001

Others

319 (24.1)

204 (25.0)

0.6

Note: For this analysis, negative and “not sure” responses were combined as “no” category. p values are Bonferroni corrected for multiple
comparisons; ES: Effect size; SD: Standard deviation. Religiously unaffiliated group includes Agnostic, Atheist, and those with no
particular religion. Others include Buddhist, Hindu, Jewish, Mormon, Muslim, Orthodox such as Greek or Russian Orthodox. * Eligible
parents = 984 participants.

As shown in Table 3, nearly 55% (95% CI: 51.7–58.7%) of booster-hesitant participants
reported having no or very little trust in COVID-19 vaccine information compared to 15%
(95% CI: 13.5–17.4%) in the non-hesitant group (p < 0.001), and the effect size, Cramer’s V,
was moderately large [35]. Among participants willing to take the booster dose, attitudes
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Table 3. Differences in the trust in the COVID-19 information
groups
(n = Dose
2138).
Intentionamong
to Take
Booster

Variable Name
Categories

Variable Name

How much trust in
Not at all
How much trust inCOVID-19 vaccine
Very little
COVID-19 vaccineinformation, n (%)
information, n (%)

Somewhat
A lot

Categories
Intention to Take BoosterYes
Dose
(n = 1322)
Yes
No
Not
at1322)
all
(3.1)
(n =
(n 41
= 816)
Very
little
162
(12.3)
41 (3.1)
197 (24.1)
Somewhat
517(31.1)
(39.1)
162 (12.3)
254
517
(39.1)
292
A lot
602(35.8)
(45.5)
602 (45.5)

Chi-Square
p Value
No
Statistics
Chi-Square
p Value(n = 816)
ES
Statistics
197 (24.1)
<0.001
508.481
254
(31.1)
<0.001
<0.001
508.481
0.488
0.13
<0.001292 (35.8)
0.13 73 (8.9)
<0.001

73
ES:(8.9)
Effect size. <0.001

ES: Effect size.
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Table 4. Vaccine literacy and vaccine confidence among booster dose hesitant and booster dose non-hesitant groups (n
2138).

Variable Name

Intention to Take Booster Dose
Yes (n = 1322)
No (n = 816)

p Valu
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An independent-sample t-test was run to determine if there were differences in functional and critical literacy (FL and CL) between vaccine hesitant and non-hesitant groups.
There was homogeneity of variances, as assessed by the Levene’s test for equality of variances (p > 0.05). The FL and CL were higher among the vaccine non-hesitant group as
compared to the hesitant group with a statistically significant mean difference of −0.49 and
−0.41, respectively (Table 4). A Welch t-test was run to determine if there were differences
in the integrative or communicative literacy and vaccine confidence index between booster
hesitant and non-hesitant participants due to the assumption of homogeneity of variances
being violated, as assessed by Levene’s test for equality of variances (p < 0.05). There were
no outliers in the data. The communicative literacy was higher among vaccine non-hesitant
group (M = 3.10, SD = 0.60) than hesitant ones (M = 2.70, SD = 0.66), a statistically significant difference, M = −0.40, 95% CI [−0.45, −0.34], t (2136) = −13.992, p < 0.001. The
vaccine confidence was higher among vaccine non-hesitant group (M = 2.43, SD = 1.08)
than hesitant ones (M = 1.20, SD = 0.66), a statistically significant difference, M = −1.23,
95% CI [−1.32, −1.17], t (2136) = −32.960, p < 0.001.
Table 4. Vaccine literacy and vaccine confidence among booster dose hesitant and booster dose non-hesitant groups
(n = 2138).
Intention to Take Booster Dose

Variable Name
Functional literacy
Integrative or communicative literacy
Critical literacy
Vaccine confidence index

Yes (n = 1322)

No (n = 816)

3.10 ± 0.75
3.10 ± 0.60
3.21 ± 0.68
2.43 ± 1.08

2.61 ± 0.74
2.70 ± 0.66
2.80 ± 0.74
1.20 ± 0.66

p Value
<0.001
<0.001
<0.001
<0.001

Note: All measures are represented as mean ± standard deviation unless stated otherwise.

As indicated in Table 5, the booster-hesitant group with “a lot” of trust in COVID-19
vaccine information had significantly low mean scores of functional, communicative, and
critical vaccine literacies compared to their non-hesitant counterparts.
Table 5. Comparing vaccine literacy and educational attainment among hesitant and non-hesitant groups, who have had “a
lot” of trust in COVID-19 information.
Trust “A Lot” in COVID-19
Vaccine Information

Booster Hesitant
73 (8.9)

Booster Non-Hesitant
602 (45.5)

p Values

95% CI of the Mean
Difference

<0.001
0.001
0.003

−0.55, −0.17
−0.041, −0.15
−0.45, −0.13

Vaccine literacy (M ± SD)
Functional literacy
Communicative literacy
Critical literacy

2.84 ± 0.82
3.00 ± 0.70
3.10 ± 0.76

3.20 ± 0.75
3.40 ± 0.54
3.43 ± 0.63

Education attainment, n (%)
High school diploma or GED
4-year college degree
Graduate level degree
Some college
Some high school

4 (5.5)
11 (15.1)
12 (16.4)
17 (23.3)
27 (37.0)

7 (1.2)
159 (26.4)
169 (28.1)
90 (15.0)
174 (28.9)

<0.001

4. Discussion
The main objectives of this study were to measure and identify factors associated
with COVID-19 vaccine booster hesitancy and assess the roles of vaccine literacy (VL) and
vaccine confidence (VC) in American adults’ willingness to take vaccine boosters. The
study was conducted before the approval of COVID-19 vaccine boosters on 23 September
2021, by the CDC’s Advisory Committee on Immunization Practices. With the arrival of
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new variants and the potential waning of vaccine protection, it appears inevitable that
boosters will play an important role in ending the COVID-19 pandemic [7,18,23,39].
The first significant finding in our data relates to vaccination uptake in the general
population. A total of 2138 adult Americans aged 18 and over participated in this study.
Sixty-eight percent (68%) of participants reported completing or initiating vaccination
against COVID-19, and the remaining thirty-two percent (32%) were unvaccinated. Over
fifty-seven percent (57%) of the participants in this study reported being fully vaccinated
against COVID-19, which is similar to the COVID-19 vaccine acceptance rate (56.9%) found
in another study [27]. Furthermore, the percentage of vaccinated individuals in the current
national study corresponds to the percentage of fully vaccinated individuals in the U.S.
population (56%) as of 5 October 2021 [40]. These data indicate that there is a significant
level of under-vaccination in the American adult population. These vaccination rates are
significantly less than the estimated herd immunity threshold (60–80%) [41–43]. The herd
immunity threshold is expected to be higher for the delta variant [44].
The second significant finding relates to self-reported willingness to accept a booster
dose in the future once they are recommended. Among participants who were fully vaccinated or have received the first dose, an overwhelming majority (79.1%) would take a
booster dose if recommended. In contrast, nearly half of the unvaccinated participants
(46.3%) reported they would not take the booster dose. This suggests that acceptance of
primary vaccination is strongly associated with willingness to accept a booster if recommended. Furthermore, a quarter of unvaccinated participants (28.6%) and thirteen percent
of vaccinated participants (13%) indicate that they are unsure whether they would accept
a booster dose. This suggests there are many individuals who have no fixed opinion on
booster shots yet and may be persuadable. The additional fact that a quarter (25.1%) of
the unvaccinated group was willing to take the booster dose demonstrates the dynamic
nature of vaccine hesitancy and the potential to change the minds of a proportion of the
vaccine hesitant group. In a previous cohort study of individuals who were hesitant to
the COVID-19 vaccine in late 2020, 32% reported receiving at least one dose, and another
37% would likely be vaccinated when re-assessed in early 2021 [45]. Perhaps, with a targeted vaccination campaign focused on those who are persuadable within hesitant groups,
vaccination uptake (and eventual booster uptake) could be increased.
4.1. Correlates of Booster Hesitancy
The data demonstrated various socioeconomic and demographic factors that are
significantly associated with vaccine booster hesitancy. Political affiliation was strongly
associated with booster hesitancy; being a registered Democrat was associated with significantly higher booster acceptance than being an Independent or a Republican. This finding
was consistent with a study by Callaghan and colleagues, which found significant vaccine
refusal among individuals who intended to vote for President Trump in 2020 and were
also identified as conservatives [46]. Next, in a bivariate analysis, education level appeared
to be highly associated with vaccine booster hesitancy. In particular, those with a college
education and graduate degrees were significantly more likely to accept booster doses than
those with only a high school education. These findings suggest that educational level
and political affiliation are strongly associated with vaccine hesitancy, which may affect
the uptake of vaccine boosters and should be considered focal points of any interventions
aimed at persuasion to increase booster uptake.
Some findings in the data deserve further consideration and perhaps further study.
With regards to gender, females were significantly more booster hesitant than males in the
bivariate analysis. This is a surprising finding. A possible explanation may be found in
persistent false messaging on social media that COVID-19 vaccines may cause infertility in
females or birth defects [47,48]. Another surprising finding is that the study did not find a
statistically significant difference in vaccine booster hesitancy among different racial or ethnic groups, which is contrary to our previous study (unpublished) and other studies [46,49],
which showed a significant level of COVID-19 vaccine hesitancy among African Americans
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and Hispanics. This suggests the factors driving vaccine booster hesitancy might differ
from hesitancy toward the initial COVID-19 vaccine. Yet another unexpected finding
relates to religious affiliation. Some studies have found that those with particular religious
leanings are more likely to be COVID-19 vaccine hesitant; consider the Callaghan study
that found that those with high levels of religiosity are more hesitant [46]. The results of
bivariate analysis in the present study demonstrate that religiously unaffiliated individuals are much more likely to be booster hesitant, while those who are religious (Roman
Catholics in particular) are less likely to be booster hesitant. It is unclear what would drive
this difference, which may warrant further exploration with expanded studies. It does
suggest that religious objections to COVID-19 are not a significant driver of persistent
vaccine hesitancy.
4.2. Vaccine Literacy and Vaccine Confidence Index
In order to assess the potential underlying causes of vaccine acceptance or hesitancy
among study participants, we utilized a validated instrument to determine vaccine literacy
(VL) and vaccine confidence, which are predictors of vaccine acceptance according to
previous reports [30]. Vaccine literacy is a person’s ability to collect and understand reliable
information about immunizations and use the acquired knowledge to make informed
decisions to benefit their health [31]. The VL tool is comprised of three components:
functional, interactive/communicative, and critical vaccine literacy. Functional literacy
refers to competence in reading and writing; interactive/communicative and critical literacy
involves advanced skills that allow individuals to derive meaning from information to
enable them to make decisions within the context of their own lives [33]. In our study,
the mean VL scores for functional, interactive (communicative), and critical literacy were
significantly higher in the group that would accept boosters than in the group hesitant to
boosters. This mirrors findings from other studies. One study used similar tools to measure
the association between VL and vaccine hesitancy; it found an association between the
interactive–critical components of VL and vaccine hesitancy, wherein those with higher
measures of interactive–critical VL are more accepting of vaccines [50]. Another crosssectional study carried out in China reported that parents with higher VL scores were more
likely to trust vaccines [51]. These findings provide further indications that there appears
to be a significant association between vaccine literacy level and vaccine booster hesitancy.
Vaccine confidence encompasses both trust in the safety and efficacy of the vaccine
itself, along with trust in the healthcare system that administers it [52]. In our data, the
average vaccine confidence index (VCI) was significantly higher in the group accepting
of boosters than in the group that was booster hesitant. This finding is consistent with a
study that measured influenza vaccine confidence among nursing home residents, which
concluded that a higher VCI was a significant predictor of vaccine uptake [53].
In addition, our data indicated a significant difference in the level of trust in COVID-19
vaccine information between those who are accepting of vaccine boosters and those who
are booster hesitant. Trust is thought to be a significant factor in vaccination uptake [54].
The lack of trust in vaccine information among those who are vaccine hesitant is partly due
to an opposing plague, which the WHO termed an “infodemic”—a plague that spreads and
supplies the public with “fake news,” misinformation, and unfounded scientific claims [55].
According to one study, individuals susceptible to this infodemic are linked with an
unwillingness to be vaccinated against COVID-19, along with a decreased tendency to
advocate for high-risk and vulnerable individuals to receive the vaccine [56]. Currently,
the vaccine booster is approved for use in such groups in addition to individuals 65 years
and older. Therefore, government agencies or healthcare providers should not assume that
the public trusts the information provided to them.
Upon exploring the trust dimension further, results of our subgroup analysis indicated
that the booster-hesitant group had significantly low mean scores of functional, communicative, and critical vaccine literacies. In addition, the level of educational attainment was
lower among hesitant individuals compared to their non-hesitant counterparts despite “a
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lot” of trust. This demonstrates that vaccine hesitancy is not only a function of trust but also
attributed to one’s perception of low risk for the disease or carefree attitudes. This lends
support to developing educational and m-health interventions based on fourth-generation
behavioral theories [57]. These interventions may include simple yet interactive messaging,
success stories, and testimonials from the community leaders [57]. To summarize, a successful vaccination campaign aiming to address and improve individuals’ ability to appraise
information and interventions to promote vaccine acceptance behavior will be critical.
4.3. Willingness to Vaccinate Children
Another important issue in the response to the pandemic is the vaccination of children [41,58]. Even though children have a lower risk of complications and disease burden
than adults [59], millions of cases and hundreds of COVID-19-related deaths in this population have been reported [58]. Furthermore, children play a substantial role in the
continued transmission of the virus within the population [8,16]. Our study demonstrates
the existence of significant hesitancy among parents to have their children vaccinated
against COVID-19. The survey asked participants whether they would have their children
vaccinated against COVID-19 once the vaccine is available and recommended for their
child. Among those parents who are vaccinated against COVID-19, about one-fifth (20.1%)
indicated that they would not have their children vaccinated, while about fourteen percent
(14.5%) were unsure. Among parents who are unvaccinated against COVID-19, about
sixty percent (61.4%) indicated that they would not have their children vaccinated, while
one-fifth (20.4%) were unsure. These data reflect high and concerning levels of COVID-19
vaccine hesitancy related to the vaccination of children, even among those parents who are
vaccinated themselves.
Our data are reflective of the findings of other studies that indicated that parents are
unwilling to have their children unvaccinated. Administration of the COVID-19 vaccine
has been authorized for the pediatric age group 12–15 years old since May 2021. As of
10 October 2021, only 39% of this group has been vaccinated [40]. According to a report
from Kaiser Family Foundation (KFF) COVID-19 Vaccine Monitor, 48% of parents of age
12–17 reported that their child received at least the first dose, and 34% of parents of children
aged 5–11 reported that they would vaccinate their child as soon as the vaccine is available
for the age group [60]. A study conducted in the U.K. reported that parents’ and guardians’
hesitancy to vaccinate children against COVID-19 when the option is available is mainly
motivated by a lower risk of complications of the virus in children [61].
It is important to point out that in our study, 14.5% of vaccinated parents and 20.4%
of unvaccinated parents remained unsure about vaccinating their children, which means
these parents are potentially persuadable and had not yet developed a firm opinion. Every
effort must be made to address the uncertainty experienced by these parents. There is
evidence that healthcare professionals can play an essential role in shaping these attitudes
by building trust, candidly addressing parents’ concerns regarding the risks and benefits
of COVID-19 and its vaccine, and providing parent-specific education [54]. This scenario
has the potential to persuade parents to get their children vaccinated and be part of the
solution to ending the pandemic.
These data also raise the question of vaccine mandates for children, as is the case
with other mandated vaccines linked to school attendance [62]. In addition to the direct
health impact COVID-19 may have on children, they also experience significant setbacks to
their wellbeing from COVID-19 impact on schools, their social circumstances, and on how
society functions. If we have a safe and effective vaccine that could protect children and
allow them to go back to school, see their friends, and have a positive social environment
once again, it becomes important to use the vaccine to achieve these goals. Given the high
levels of hesitancy to have children vaccinated, these considerations provide a potential
justification for instituting vaccine mandates for children once COVID-19 vaccines are
demonstrated to be safe and effective, licensed, and widely available for children.

Vaccines 2021, 9, 1424

12 of 16

4.4. Strength and Limitations
This study provides significant insight into factors associated with COVID-19 vaccine
booster hesitancy, as well as vaccine hesitancy that may affect vaccine uptake among
children. A notable strength of the study is that the sample is nationally representative.
Furthermore, the percentage of fully vaccinated individuals in the study (57%) corresponds to the percentage of fully vaccinated individuals in the U.S. population (56%) as
of 5 October 2021 [39]. To our knowledge, this is the first study to explore the association
between vaccine confidence, vaccine literacy, and booster dose acceptability. The study has
several limitations. First, this study arises from a cross-sectional design where data reflects
a snapshot of willingness to take the booster vaccine when, in reality, individual attitudes
are dynamic and evolving. Second, as is the case for all cross-sectional studies, causality
cannot be inferred from this design. Third, though our findings share similar outcomes
with previous non-COVID-19 vaccine studies, we cannot confidently confirm our results’
generalizability due to the unique context created by the pandemic. Fourth, web-based
surveys are easily susceptible to the effects of self-selection bias—a bias that comes from a
non-representative sample restricted to internet users—and often face low response rates.
Finally, our study is susceptible to self-reporting, social desirability, and language biases.
This study did not attempt to seek an objective correlation between VCI and VL.
However, measuring and understanding their correlation and effects on each other, in a
similar setting and context, promise to provide invaluable information in understanding
and mitigating vaccine hesitancy. Furthermore, as is the case with vaccine hesitancy, VL
and VC are dynamic and context-dependent. Hence, measuring and tracking them over a
period of time is essential and represents avenues for further study.
5. Conclusions
This article presents the results of a cross-sectional study involving a representative
sample of the American population in terms of geography, gender, race, and ethnicity. The
data present important insights related to COVID-19-vaccine booster hesitancy, potential
factors related to booster hesitancy, and future COVID-19 vaccination uptake. A large
majority of those who have been vaccinated against COVID-19 with an initial series report
the intention to receive booster shots when boosters become necessary. This is good news,
given the fact that booster shots will inevitably play an important role in our response
to COVID-19. Of those who were unvaccinated, a significant proportion indicated that
they would receive a booster shot or that they were unsure about booster shots, which
may indicate that these persons are persuadable. This highlights the need for data on
factors that relate to COVID-19 vaccine hesitancy and consideration of the ways to respond
to the specific needs of such persons to increase the vaccination uptake. This study also
demonstrated that education and vaccine literacy play a significant role in COVID-19
vaccine booster uptake intention. Thought must be given to communicating vaccine
science in ways that are accessible to those with lower levels of education or lower levels
of vaccine literacy to increase the vaccination uptake. Furthermore, acceptance of vaccine
boosters was significantly associated with political affiliation, which underlines the way in
which the issue of COVID-19 vaccinations has become politicized. It is an urgent priority
to find ways to change this; COVID-19 vaccination is not and should not be a partisan
political issue but should be something society can coalesce around. Ways should be sought
to remove the politicization around vaccines and to communicate in ways that can draw
in adherents of different political persuasions and views. These data and conclusions are
important in consideration of future policies and public health interventions aimed at
increasing the COVID-19 vaccination uptake and vaccine uptake more generally.
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